Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04150042 · ClinicalTrials.gov registry record · Phase 1
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
A Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by General Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT04150042 is a Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by General Oncology. The registered enrollment target is 24 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04150042, a Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by General Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, vitamin B12b, and vitamin C with autologous hematopoietic stem cell infusion. A dose-escalation schedule is being employed for the vitamin C.
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Vitamin C
- DRUG BCNU
- DRUG Vitamin B12B
- DEVICE Autologous Hematopoietic Stem Cells
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-01-13 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04150042
The ClinicalTrials.gov registry entry for NCT04150042 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (94% lower). The listed sponsor is General Oncology, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.
NCT04150042 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04150042 about?
NCT04150042 is a clinical study titled "SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells". The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, vitamin B12b, and vitami...
What is the current status of trial NCT04150042?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-01-13. Estimated completion is 2028-12.
What conditions does trial NCT04150042 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Breast Cancer Metastatic.
What interventions are being tested in trial NCT04150042?
The interventions under investigation include: Melphalan (DRUG), Vitamin C (DRUG), BCNU (DRUG), Vitamin B12B (DRUG), Autologous Hematopoietic Stem Cells (DEVICE).
Who is sponsoring clinical trial NCT04150042?
This trial is sponsored by General Oncology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04150042 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.